Orchestra BioMed dips 11%, prices $75M public offering at $5 per share
What it means
- What to watch: The headline hangs on one number (11%) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $OBIO -6.33% in the latest session.
- Timing: It landed while New York slept, so the session change beside it belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
$OBIO last changed hands at $5.62, -6.33% on the session, 14% below its 52-week high of $6.50 and 62% above its low of $3.46 — in the upper part of the range. Over the year it has ranged 88% from low to high: a wide band, so a several-percent week is just a week. These are latest-session quotes, not live prices — the live tape is on the $OBIO page.
How much coverage it is getting
Nothing else on $OBIO in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$OBIO earnings in 3 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $OBIO page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $OBIO is from its high, or how this week's coverage compares.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $OBIO. It carried $75 million, $5 and 11%, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.